Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease with Option for an Additional Two Years of Treatment

Trial Profile

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease with Option for an Additional Two Years of Treatment

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Gantenerumab (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms SCarlet RoAD
  • Sponsors Roche
  • Most Recent Events

    • 20 Jul 2017 Results of analysis estimating clinically relevant change and difference thresholds for the clinical dementia rating -sum of boxes using patient data from ADNI, NCT01224106 and NCT01343966 trials presented at the Alzheimer's Association International Conference 2017
    • 20 Jul 2017 Results of first report exploring correlation between vascular pathology at baseline and occurrence of ARIA-E in prodromal AD patients presented at the Alzheimer's Association International Conference 2017
    • 20 Jul 2017 Results evaluating the effect of 6 months dosing on the rate of amyloid-related imaging abnormalities, presented at the Alzheimer's Association International Conference 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top